FDA-approved Digestive & weight

Dasiglucagon

Dasiglucagon is a glucagon analog. It is filed in this library under digestive & weight, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.

Regulatory status

Dasiglucagon has an FDA-approved product on the U.S. market, marketed as Zegalogue under application NDA214231.

The current label is held by Novo Nordisk.

From the FDA label

What Dasiglucagon is approved to treat

® is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.Quoted from the FDA-approved prescribing information

The evidence

What has actually been published

One source on Dasiglucagon, resolved to its journal of record. The title is listed so you can judge the evidence rather than take a summary on trust.

Nearby

Other peptides acting on digestive & weight

Markers on this pathway

What is measured when blood sugar and insulin is assessed

Dasiglucagon's FDA-approved label indicates it for glycemic control or for a glucose emergency. These are the markers clinicians use when assessing blood sugar and insulin. They are listed here so you can read about them, not as a statement that Dasiglucagon changes any of them.

Not sure what applies to you?

A 60-second questionnaire, reviewed by a U.S.-licensed physician.

Find my protocol

Educational reference only. This page explains what has been published about Dasiglucagon. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.

Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.

All 150 peptides